Compounded GLP-1 week two: what the science says about early effects

What's this video probably claiming?

Based on the caption, this creator is documenting week two of a compounded GLP-1 medication obtained through Hers, a telehealth platform. She reports minimal side effects in week one, persistent food noise, and a possible early satiety effect. This is a classic early-adopter experience log, the kind that racks up views because it feels relatable and unsponsored. The implicit claims here are worth examining: that compounded GLP-1s work quickly enough to notice effects in week one, that lack of side effects is a reasonable expectation, and that appetite reduction ("fuller faster") is a reliable early signal. These are all plausible claims, but the nuance matters quite a bit. She's also framing this within a Weight Watchers community context, which layers behavioral modification on top of pharmacotherapy, a combination that has real clinical data behind it but rarely gets discussed honestly on TikTok.

What does the science actually show?

GLP-1 receptor agonists like semaglutide work by slowing gastric emptying and acting on hypothalamic satiety centers. The appetite suppression effect is real and documented. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that 2.4mg weekly semaglutide produced around 14.9% mean body weight reduction over 68 weeks in adults without diabetes. But here's the catch: those results came at maintenance doses that most people don't reach until week 16 or later, because the standard titration protocol starts at 0.25mg weekly. At week two, most patients are still at the starting dose, which is designed to minimize side effects, not maximize efficacy. Early satiety sensations at this stage are plausible but are likely subtle and hard to distinguish from placebo response or behavioral changes. A 2022 review by Drucker in Cell Metabolism confirmed that gastric emptying effects appear early, but appetite suppression at the hypothalamic level scales with dose.

Where does the social media noise diverge from clinical reality?

The framing that "no real side effects" in week one is a good sign deserves scrutiny. The most common adverse effects of semaglutide, nausea, vomiting, and constipation, often emerge during dose escalation, not at the initial 0.25mg dose. Expecting week one to be representative of the full treatment experience is a mistake a lot of creators make, and it can set followers up for surprise when they hit their first dose increase. The "food noise" observation is interesting because it has no standardized clinical definition. Researchers are starting to take it seriously, but it does not appear as a primary endpoint in any major GLP-1 trial to date. A 2023 qualitative study by Stokes et al. in Obesity Science and Practice documented patient-reported food noise reduction as a secondary theme, but the evidence is anecdotal at this stage. Viewers should also understand that compounded semaglutide and brand-name Wegovy are not the same product. The FDA has explicitly stated compounded drugs are not FDA-approved, regardless of active ingredient similarity.

What should you actually know?

If you are watching week-by-week GLP-1 content on TikTok and using it to benchmark your own experience, understand the limitations. Individual response varies significantly based on starting dose, body composition, insulin sensitivity, and gut microbiome factors. The STEP trials enrolled highly controlled populations; your results will differ. Week two on a titration protocol is genuinely early, and any effects felt this quickly are probably subtle. The compounded GLP-1 market is also in legal flux: the FDA removed semaglutide from the drug shortage list in February 2025, which means compounding pharmacies face new restrictions on producing it. Platforms like Hers are navigating this in real time. That is not an argument against using these medications under medical supervision, but it is an argument for having a prescribing clinician who is paying attention. Behavioral tools like Weight Watchers have their own evidence base for modest weight loss, and combining them with GLP-1 therapy has some clinical support, but the interaction effects are not well-studied at scale.